Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity
- 129 Downloads
Adenosine deaminase (ADA) has been found to be involved in autoimmune disease progression. To assess the potential application of serum ADA activity in diagnosing systemic lupus erythematosus (SLE) and evaluating SLE disease activity, we investigated the serum ADA activity of 120 SLE patients and 120 healthy controls in the present study. The results showed that serum ADA activity in SLE patients was significantly increased (median (IQR) = 14 (11–19) U/L) compared with that in healthy controls (median (IQR) = 8 (7–10) U/L). Based on a receiver operating characteristic curve analysis, the optimal cut-off value for using serum ADA activity to diagnose SLE patients was 10.5 U/L (specificity, 84.2%; sensitivity, 78.3%). The diagnostic performance of serum ADA activity for SLE patients was better than that of other conventional haematology markers. Moreover, serum ADA activity displayed an increasing trend with increasing SLE disease activity. Spearman’s correlation analysis showed that serum ADA activity was positively correlated with SLE disease activity. These findings suggest that serum ADA activity could be a diagnostic marker for SLE; moreover, measuring serum ADA activity may be helpful for evaluating and monitoring the disease activity of SLE patients.
KeywordsSLE ADA Diagnosis Disease activity
This study was supported by the National Natural Science Foundation of China (no. 81572974).
Compliance with ethical standards
This project was approved by the Ethics Committee of the Tangdu Hospital, Fourth Military Medical University. Ethical approval was obtained from the Ethics Committee of Tangdu Hospital, Fourth Military Medical University (TDLL-20151209), and informed consent was not required.
Conflict of interests
The authors declare that they have no conflict of interest.
- 3.Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev. 1998;161(1):27–42. https://doi.org/10.1111/j.1600-065X.1998.tb01569.x.CrossRefPubMedGoogle Scholar
- 5.Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38. https://doi.org/10.1001/jama.2014.9132.
- 6.Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. 2016;128(1):45–54. https://doi.org/10.1182/blood-2016-01-688226.
- 9.Sauer AV, Brigida I, Carriglio N, Hernandez RJ, Scaramuzza S, Clavenna D, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood. 2012b;119(6):1428–39. https://doi.org/10.1182/blood-2011-07-366781.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Nalesnik M, Nikolic JM, Jandric S. Adenosine deaminase and C-reactive protein in diagnosing and monitoring of rheumatoid arthritis. Medicinski Glasnik: Off Publ Med Assoc Zenica-Doboj Canton, Bosnia and Herzegovina. 2011;8(1):163–8.Google Scholar
- 15.Saghiri R, Ghashghai N, Movaseghi S, Poursharifi P, Jalilfar S, Bidhendi MA, et al. Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern. Rheumatol Int. 2012;32(6):1633–8. https://doi.org/10.1007/s00296-011-1836-8.CrossRefPubMedGoogle Scholar
- 17.Demir G, Borman P, Ayhan F, Ozgun T, Kaygisiz F, Yilmez G. Serum adenosine deaminase level is high but not related with disease activity parameters in patients with rheumatoid arthritis. Open Rheumatol J. 2014;8(1):24–8. https://doi.org/10.2174/1874312901408010024.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Jolly M, Smaron M, Olsen Utset T, Ellman M. Are isolated antinucleolar antibodies a marker of scleroderma? J Clin Rheumatol: Pract Rep Rheumatic Musculoskelet Dis. 2003;9(5):291–5. https://doi.org/10.1097/01.rhu.0000089790.80026.f4.CrossRefGoogle Scholar